To validate the association between CD47 expression and survival we observed in our gynecology cancer patients, we tested CD47 expression as a biomarker to predict tumor immune response using tumor pre-treatment expression profile database, using the online tool TIDE: Tumor Immune Dysfunction and Exclusion as described in Method. The gene discussed is CD47; the disease is neoplasm.